FR2571615A1 - New processes and compositions for slowing down hair regrowth after depilation - Google Patents
New processes and compositions for slowing down hair regrowth after depilation Download PDFInfo
- Publication number
- FR2571615A1 FR2571615A1 FR8411226A FR8411226A FR2571615A1 FR 2571615 A1 FR2571615 A1 FR 2571615A1 FR 8411226 A FR8411226 A FR 8411226A FR 8411226 A FR8411226 A FR 8411226A FR 2571615 A1 FR2571615 A1 FR 2571615A1
- Authority
- FR
- France
- Prior art keywords
- fce
- depilation
- hair regrowth
- compositions
- egf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 title claims abstract description 6
- 230000035617 depilation Effects 0.000 title abstract 2
- 230000003659 hair regrowth Effects 0.000 title abstract 2
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 5
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 4
- 230000000699 topical effect Effects 0.000 claims abstract description 3
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract 3
- 210000004209 hair Anatomy 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000000149 penetrating effect Effects 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 4
- 230000004071 biological effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000605 extraction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A61Q7/02—Preparations for inhibiting or slowing hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
La présente invention concerne un nouveau procédé permettant de prolonger dans le temps l'effet d'une épilation réalisée par des méthodes connues, ainsi que les compositions permettant la mise en oeuvre de ce procédé.The present invention relates to a new process making it possible to prolong the effect of hair removal performed by known methods over time, as well as the compositions allowing the implementation of this process.
La demanderesse a précédemment publié un procédé (Brevet Français nO 2 380 775) permettant d'obtenir ce même résultat. Poursuivant des travaux sur le même sujet, elle a découvert qu'il était avantageusement possible d'utiliser à cet effet un extrait d'origine animale appelé Facteur de
Croissance Epidermique en agrégé FCE ou EGF (d'après son appellation anglo-saxonne). Cette substance est déjà connue pour son effet trophique sur l'épiderme, dont les applications cosmétiques font l'objet de la demande de brevet français nO 82 - 15559 au nom de la demanderesse.The Applicant has previously published a process (French Patent No. 2,380,775) allowing this same result to be obtained. Continuing work on the same subject, she discovered that it was advantageously possible to use for this purpose an extract of animal origin called Facteur de
Epidermal growth in FCE or EGF aggregation (according to its Anglo-Saxon name). This substance is already known for its trophic effect on the epidermis, the cosmetic applications of which are the subject of French patent application No. 82 - 15559 in the name of the applicant.
Le FCE présente également des propriétés inhibitrices sur les cellules du follicule pileux, influençant la vitesse de repousse du poil, surtout lorsque celui-ci est néo-formé. Le FCE présente peu sinon aucune activité sur le poil déjà formé. Son activité inhibitrice s'exerce au cours de la phase anagène du poil.FCE also has inhibitory properties on the cells of the hair follicle, influencing the rate of regrowth of the hair, especially when the hair is neo-formed. The FCE shows little if any activity on the hair already formed. Its inhibitory activity is exerted during the anagen phase of the hair.
Les inventeurs ont découvert que le FCE utilisé à des concentrations faibles et par voie cutanée permettait de ralentir de façon appréciable la repousse des poils, sans effets secondaires particuliers. On reviendra plus loin sur ce dernier point, important quant à l'utilisation cosmétique.The inventors have discovered that the FCE used at low concentrations and by the cutaneous route makes it possible to appreciably slow down the regrowth of hair, without any particular side effects. We will return to this last point later, which is important as regards cosmetic use.
L'époque idéale pour ces applications se situe après une épilation effectuée à la cire, par des moyens électriques, ou toute autre méthode aboutissant à la destruction du poil déjà formé. L'action du FCE, selon l'invention, n'est pas une action dépilatrice proprement dite, mais une action retardant la repousse du nouveau poil.The ideal time for these applications is after hair removal with wax, by electric means, or any other method leading to the destruction of the hair already formed. The action of the FCE, according to the invention, is not an actual depilatory action, but an action delaying the regrowth of the new hair.
Le procédé selon l'invention consiste donc en des applications topiques de préparations contenant du FCE, en proportions définies, suffisantes pour obtenir un effet appréciable, mais néanmoins faibles de façon à ne pas présenter d'effets secondaires. Etant donné le coût relativement élevé du
FCE, la présentation préférée du produit est telle que
- Le FCE est conditionné séparément à l'état sec, de
préférence lyophilisé.The method according to the invention therefore consists of topical applications of preparations containing FCE, in defined proportions, sufficient to obtain an appreciable effect, but nevertheless weak so as to have no side effects. Given the relatively high cost of
FCE, the preferred product presentation is such that
- The FCE is packaged separately in the dry state, from
preferably freeze-dried.
- L'excipient hydrosoluble émulsionné ou non, est formulé
de façon à être le plus pénétrant possible.- The water-soluble excipient, emulsified or not, is formulated
so as to be as penetrating as possible.
Le produit est reconstitué par l'utilisateur lors de la
première utilisation. Le produit est étalé avec un petit
pinceau, ou par tout autre moyen minimisant les pertes.The product is reconstituted by the user during the
first use. The product is spread with a small
brush, or by any other means minimizing losses.
A titre d'exemple non limitatif, on donne la composition d'un produit qui a été utilisé avec succès lors de tests sur volontaires
PRODUIT ACTIF
-F.C.E. I mg
-Ballast de lyophilisation
(facultatif) 20 mg EXCIPIENT
- Eau qsp 100 g
- Propylene Glycol 6
- Polyéthylène glycol 400 15
- Lécithine de soja hydrodispersible 1,5
- Menthol hydrosoluble 0,4
- Parfum 0,3
- Polysorbate 20 2,5
- Conservateur qs
En fonction du pouvoir de pénétration de l'excipient, on peut utiliser des doses plus ou moins importantes de produit actif. Dans le procédé selon l'invention, des doses de 0,1 mg à 10 mg de FCE, pour 100 g de produit reconstitué final, sont convenables, dans l'état actuel des travaux de la demanderesse.By way of nonlimiting example, the composition of a product which has been used successfully in tests on volunteers is given.
ACTIVE PRODUCT
-FCE I mg
- Lyophilization ballast
(optional) 20 mg EXCIPIENT
- Water qs 100 g
- Propylene Glycol 6
- Polyethylene glycol 400 15
- Water-dispersible soy lecithin 1.5
- Water-soluble menthol 0.4
- Perfume 0.3
- Polysorbate 20 2.5
- Preservative qs
Depending on the penetrating power of the excipient, more or less large doses of active product can be used. In the process according to the invention, doses of 0.1 mg to 10 mg of FCE, per 100 g of final reconstituted product, are suitable, in the current state of the work of the applicant.
Bien entendu, on peut également envisager toute autre forme de présentation cosmétique, y compris des produits prêts à l'emploi, dans la mesure où leurs excipients sont étudiés de façon à préserver intactes les propriétés biologiques du FCE.Of course, one can also envisage any other form of cosmetic presentation, including ready-to-use products, insofar as their excipients are studied so as to preserve intact the biological properties of FCE.
Le FCE pourra provenir d'extraction d'organes, d'extraction de micro-organismes, ou de synthèse. On peut également envisager l'utilisation de tout peptide analogue du FCE, ou encore tout fragmert peptidique de FCE, présentant les mêmes propriétés biologiques que celui-ci. Un exemple d'analogue, est l'urogastrone, un peptide isolé de l'urine humaine, qui présente de grandes similitudes de structure et d'activité biologique avec le FCE extrait de glande submaxillaire de souris (voir par exemple DEMBINSKI A. ét coll., J. Physiol., 1982, 325, 35-42).The FCE can come from organ extraction, microorganism extraction, or synthesis. One can also consider the use of any peptide analog of FCE, or any peptide fragmert of FCE, having the same biological properties as the latter. An example of an analog is urogastrone, a peptide isolated from human urine, which has great similarities in structure and biological activity with FCE extracted from mouse submaxillary gland (see for example DEMBINSKI A. et al. ., J. Physiol., 1982, 325, 35-42).
On entend bien entendu par FCE le produit actif pur, répondant aux critères chimiques habituels de pureté, et aux critères biologiques d'activité (test de précocité de l'ouverture des paupières et de la percée des dents chez le souriceau nouveau-né, décrit en particulier par COHEN S., (J. Biol. Chem., 1962, 237, 1555-1562). Toute autre forme brute ou diluée de FCE pourra être uti sous sous réserve
1) de se ramener aux quantités de FCE pur citées ci-dessus,
c'est-à-dire 0,1 mg à 10 mg de FCE pur pour 100 g de
préparation termirée.Naturally, by FCE is meant the pure active product, meeting the usual chemical criteria of purity, and the biological criteria of activity (test of precocity of the opening of the eyelids and of the breakthrough of the teeth in the newborn mice, described in particular by COHEN S., (J. Biol. Chem., 1962, 237, 1555-1562) Any other raw or diluted form of FCE may be used subject to reservation
1) to reduce to the quantities of pure FCE mentioned above,
i.e. 0.1 mg to 10 mg of pure FCE per 100 g of
preparation finished.
2) que l'activité biologique du FCE ne soit pas masquée par
d'autres activités compétitives ou antagonistes. 2) that the biological activity of FCE is not masked by
other competitive or antagonistic activities.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8411226A FR2571615B1 (en) | 1984-07-12 | 1984-07-12 | NOVEL METHODS AND COMPOSITIONS FOR SLOWING DOWN GROWTH OF HAIR AFTER HAIR REMOVAL |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8411226A FR2571615B1 (en) | 1984-07-12 | 1984-07-12 | NOVEL METHODS AND COMPOSITIONS FOR SLOWING DOWN GROWTH OF HAIR AFTER HAIR REMOVAL |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2571615A1 true FR2571615A1 (en) | 1986-04-18 |
| FR2571615B1 FR2571615B1 (en) | 1993-11-05 |
Family
ID=9306147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8411226A Expired - Fee Related FR2571615B1 (en) | 1984-07-12 | 1984-07-12 | NOVEL METHODS AND COMPOSITIONS FOR SLOWING DOWN GROWTH OF HAIR AFTER HAIR REMOVAL |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2571615B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5130142A (en) * | 1990-10-31 | 1992-07-14 | The Practer & Gamble Company | Hair growth regulating composition comprising epithelium cell supernatant-derived growth factor |
| US9216304B2 (en) | 2010-03-26 | 2015-12-22 | The Gillette Company | Method of depilation and depilatory kit |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2380775A1 (en) * | 1977-02-22 | 1978-09-15 | Sederma Sarl | "AFTER-DEPILATION" COMPOSITION PROMOTING A PROGRESSIVE SLOWING OF HAIR REGROWTH |
| GB2082186A (en) * | 1980-08-04 | 1982-03-03 | Commw Scient Ind Res Org | Defleecing with egf |
| JPS615006A (en) * | 1984-06-19 | 1986-01-10 | Sanki Shoji Kk | Agent for skin |
-
1984
- 1984-07-12 FR FR8411226A patent/FR2571615B1/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2380775A1 (en) * | 1977-02-22 | 1978-09-15 | Sederma Sarl | "AFTER-DEPILATION" COMPOSITION PROMOTING A PROGRESSIVE SLOWING OF HAIR REGROWTH |
| GB2082186A (en) * | 1980-08-04 | 1982-03-03 | Commw Scient Ind Res Org | Defleecing with egf |
| JPS615006A (en) * | 1984-06-19 | 1986-01-10 | Sanki Shoji Kk | Agent for skin |
Non-Patent Citations (1)
| Title |
|---|
| PATENT ABSTRACTS OF JAPAN, vol. 10, no. 144 (C-349)[2201], 27 mai 1986; & JP-A-61 005 006 (SANKI SHOJI K.K.) 10-01-1986 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5130142A (en) * | 1990-10-31 | 1992-07-14 | The Practer & Gamble Company | Hair growth regulating composition comprising epithelium cell supernatant-derived growth factor |
| US9216304B2 (en) | 2010-03-26 | 2015-12-22 | The Gillette Company | Method of depilation and depilatory kit |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2571615B1 (en) | 1993-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2005695C (en) | Use of salicylated derivatives for the treatment of skin aging | |
| EP0759292B1 (en) | Use of alpha type melanocytes stimulating hormone derivatives to stimulate the hairgrowth | |
| JPH05194163A (en) | Cosmetic composition | |
| EP1175891A1 (en) | Use of non prostanoic agonists of EP-2 and/or EP-2 prostaglandin receptors as cosmetic agent for reducing or stopping hair loss | |
| CA1275626C (en) | Use of lupinus sues powder in the manufacture of cosmetic or dermopharmaceutical compositions, and compositiond containing the same | |
| FR2751537A1 (en) | USE OF HONEY AS A KERATOLYTIC AGENT, IN PARTICULAR FOR IMPROVING SKIN DYE SKIN AND TREATING WRINKLES | |
| KR19990068298A (en) | Tooth paste-composition containing rose-seed oil | |
| EP0179675B1 (en) | Lipid compositions favouring the growth of phaners, and cosmetic products containing them | |
| EP0681827A1 (en) | Use of bioflavonoids as keratineous phaners protection agent | |
| EP0881902B1 (en) | Combinations of peroxide lipids and organosilicon compounds, cosmetic and dermatological compositions containing same, and uses thereof, in particular for treating alopecia | |
| FR2514643A1 (en) | COPPER LANOLATE AND ANTI-ACNE COSMETIC COMPOSITIONS CONTAINING THE SAME | |
| JP2000229834A (en) | Cosmetic | |
| JP2003528123A (en) | Cosmetic composition having a delay effect on the regeneration of unwanted hair | |
| CA2189161C (en) | Hair dye composition containing ground plants or portions of plants of the species impatiens balsamina, and application thereof | |
| FR2791255A1 (en) | Anti-androgenic compositions contain a vegetable-based complex derived from sabal, marrow and epilobium, for prevention of hair regrowth, loss of hair, and seborrhea | |
| EP0829256B1 (en) | Use of RXR retinoid receptor agonists to stimulate or induce hair growth and/or stop their loss | |
| EP0663812B1 (en) | Use of alkylpolyglycosides and/or o-acylated derivatives of glucose for treating hair loss | |
| WO2018172379A1 (en) | Use of a copaifera extract to combat alopecia and seborrhea | |
| FR2571615A1 (en) | New processes and compositions for slowing down hair regrowth after depilation | |
| EP0243248A1 (en) | Compositions for the treatment of baldness and alopecia | |
| FR3099699A1 (en) | Achenes extract from Silybum marianum (L.) Gaertn. to promote hair growth | |
| CA1297411C (en) | Alkylene diamino quinazoline derivatives based composition for activing and stimulating hair growth and reducing hair loss | |
| JPH01242516A (en) | Hair tonic, hair shampoo and hair growing promoter | |
| JP2002316917A (en) | Hair tonic/hair growing agent, gray hair improving cosmetic | |
| CH667991A5 (en) | COSMETIC COMPOSITIONS FOR THE TREATMENT OF HAIR AND SCALP CONTAINING, A WATER-SOLUBLE HOMO OR COPOLYMER CONTAINING BETA-ALANINE PATTERNS AND NICOTINIC ACID OR ONE OF ITS ESTERS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CD | Change of name or company name | ||
| TP | Transmission of property | ||
| ST | Notification of lapse | ||
| ST | Notification of lapse | ||
| ST | Notification of lapse |